Literature DB >> 32441353

Traumatic injury results in prolonged circulation of ultralarge von Willebrand factor and a reduction in ADAMTS13 activity.

Mitchell R Dyer1, William E Plautz2, Margaret V Ragni3, Wyeth Alexander2, Shannon Haldeman1, Jason L Sperry1, Francis X Guyette4, Brian S Zuckerbraun1, Marian A Rollins-Raval5,6, Jay S Raval5,6, Matthew D Neal1.   

Abstract

BACKGROUND: Increases in plasma von Willebrand Factor (VWF) levels, accompanied by decreases in the metalloprotease ADAMTS13, have been demonstrated soon after traumatic injury while downstream effects remain unclear. STUDY DESIGN AND METHODS: A cohort of 37 injured trauma patients from a randomized control trial investigating the use of prehospital plasma transfusion were analyzed for activity and antigen levels of ADAMTS13 and VWF at 0 and 24 hours after admission. Relevant clinical data were abstracted from the medical records. Trauma patient plasma was analyzed via agarose gel electrophoresis to evaluate the effects of injury on VWF multimer composition compared to healthy controls.
RESULTS: von Willebrand factor levels were elevated at presentation (189% [110%-263%] vs. 95% [74%-120%]), persisting through 24 hours (213% [146%-257%] vs. 132% [57%-160%]), compared to healthy controls. Ultralarge VWF (UL-VWF) forms were elevated in trauma patients at both 0 and 24 hours, when compared to pooled normal plasma (10.0% [8.9%-14.3%] and 11.3% [9.1%-21.2%], respectively, vs. 0.6%). Circulating plasma ADAMTS13 activity was decreased at 0 hours (66% [47%-86%] vs. 100% [98%-100%]) and at 24 hours (72.5% [56%-87.3%] vs. 103% [103%-103%]) in trauma patients. ADAMTS13 activity independently predicted the development of coagulopathy and correlated with international normalized ratio, thromboelastography values, injury severity, and blood product transfusion.
CONCLUSION: Traumatic injury is associated with acute coagulopathy that is characterized by increased UL-VWF multimers and reduction in ADAMTS13, which correlates with blood loss, transfusion requirement, and injury severity. These findings suggest the potential for future trials targeting ADAMTS13 repletion to enhance clearance of VWF multimers.
© 2020 AABB.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32441353     DOI: 10.1111/trf.15856

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  5 in total

1.  Plasma and rhADAMTS13 reduce trauma-induced organ failure by restoring the ADAMTS13-VWF axis.

Authors:  Derek J B Kleinveld; Derek D G Simons; Charlotte Dekimpe; Shannen J Deconinck; Pieter H Sloos; M Adrie W Maas; Jesper Kers; Joshua Muia; Karim Brohi; Jan Voorberg; Karen Vanhoorelbeke; Markus W Hollmann; Nicole P Juffermans
Journal:  Blood Adv       Date:  2021-09-14

Review 2.  Diverse activities of von Willebrand factor in traumatic brain injury and associated coagulopathy.

Authors:  Xin Xu; Rosemary Kozar; Jianning Zhang; Jing-Fei Dong
Journal:  J Thromb Haemost       Date:  2020-10-06       Impact factor: 5.824

Review 3.  Trauma-induced coagulopathy.

Authors:  Ernest E Moore; Hunter B Moore; Lucy Z Kornblith; Matthew D Neal; Maureane Hoffman; Nicola J Mutch; Herbert Schöchl; Beverley J Hunt; Angela Sauaia
Journal:  Nat Rev Dis Primers       Date:  2021-04-29       Impact factor: 65.038

4.  Quantification of von Willebrand factor and ADAMTS-13 after traumatic injury: a pilot study.

Authors:  Taleen A MacArthur; Julie Goswami; Laurie Moon Tasson; Alexander Tischer; Kent R Bailey; Grant M Spears; Jing-Fei Dong; Matthew Auton; Rosemary Kozar; Myung S Park
Journal:  Trauma Surg Acute Care Open       Date:  2021-04-05

Review 5.  Platelet dysfunction after trauma: From mechanisms to targeted treatment.

Authors:  Pieter H Sloos; Paul Vulliamy; Cornelis van 't Veer; Anirban Sen Gupta; Matthew D Neal; Karim Brohi; Nicole P Juffermans; Derek J B Kleinveld
Journal:  Transfusion       Date:  2022-06-24       Impact factor: 3.337

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.